HC Wainwright Comments on Balchem Co.’s Q1 2025 Earnings (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Balchem in a report released on Wednesday, July 31st. HC Wainwright analyst R. Selvaraju now anticipates that the basic materials company will post earnings of $1.04 per share for the quarter, up from their prior forecast of $1.00. HC Wainwright has a “Buy” rating and a $185.00 price target on the stock. The consensus estimate for Balchem’s current full-year earnings is $3.91 per share. HC Wainwright also issued estimates for Balchem’s Q2 2025 earnings at $1.08 EPS, Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.16 EPS and FY2025 earnings at $4.40 EPS.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings data on Friday, May 3rd. The basic materials company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Balchem had a net margin of 12.52% and a return on equity of 10.94%. The business had revenue of $239.66 million for the quarter, compared to analysts’ expectations of $234.12 million.

Separately, StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a report on Monday.

Balchem Price Performance

BCPC opened at $175.99 on Friday. The business has a fifty day moving average of $160.28 and a 200 day moving average of $153.17. Balchem has a 52-week low of $110.74 and a 52-week high of $186.03. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.71 billion, a P/E ratio of 49.71, a PEG ratio of 5.67 and a beta of 0.67.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Signaturefd LLC increased its position in Balchem by 123.0% during the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after buying an additional 91 shares in the last quarter. Principal Securities Inc. acquired a new position in Balchem during the 4th quarter valued at about $28,000. Bessemer Group Inc. increased its position in Balchem by 568.9% during the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after buying an additional 256 shares in the last quarter. GAMMA Investing LLC acquired a new position in Balchem during the 4th quarter valued at about $56,000. Finally, YHB Investment Advisors Inc. acquired a new position in Balchem during the 1st quarter valued at about $69,000. 87.91% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Balchem news, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total value of $764,900.00. Following the completion of the sale, the director now directly owns 9,009 shares in the company, valued at approximately $1,378,196.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, SVP Michael Robert Sestrick sold 1,929 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $154.45, for a total value of $297,934.05. Following the completion of the transaction, the senior vice president now directly owns 4,878 shares of the company’s stock, valued at approximately $753,407.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David B. Fischer sold 5,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total value of $764,900.00. Following the completion of the transaction, the director now directly owns 9,009 shares of the company’s stock, valued at $1,378,196.82. The disclosure for this sale can be found here. Company insiders own 1.25% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.